School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

CERUS CORP CERS

Healthcare · Medical Devices

$2.26last close 2026-10-12 · market cap $455.45M · delayed data

Trailing returns

1M-9.24%
3M-27.56%
6M+19.58%
1Y+41.25%
5Y-63.01%

Basis: Adjusted daily closes.

What it does

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Open CERS in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies